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Abstract 
Radiogalium chelates are important for diagnostic imaging in nuclear medicine (PET 
and-scintigraphy). Micelles are adequate colloidal vehicles for the delivery of 
therapeutic and diagnostic agents to organs and tissues. In this paper we describe the 
synthesis and in vitro and in vivo studies of a series of micelles-forming Ga(III) chelates 
targeted for the liver. The amphiphilic ligands are based on NOTA (NOTA = 1,4,7-
triazacyclonoane-N,N’N’’-triacetic acid) and bear a -alkyl chain in one of the pendant 
acetate arms (the size of the chain changes from four to fourteen carbon atoms). A 
multinuclear NMR study (1H, 13C, 27Al and 71Ga) gave some insights into the structure 
and dynamics of the metal chelates in solution, consistent with their rigidity and 
octahedral or pseudo-octahedral geometry. The critical micellar concentration of the 
chelates was determined using a fluorescence method and 27Al NMR spectroscopy 
(Al(III) was used as a surrogate of Ga(III)), both showing similar results and suggesting 
that the chelates of NOTAC6 form pre-micellar aggregates. The logP (octanol-water) 
determination showed enhancement of the lipophilic character of the Ga(III) chelates 
with the increase of the number of carbons in the -alkyl chain. Biodistribution and -
scintigraphic studies of the 67Ga(III) labeled chelates were performed on Wistar rats, 
showing higher liver uptake for [67Ga](NOTAC8) in comparison to [67Ga](NOTAC6), 
consistent with a longer -alkyl chain and a higher lipophilicity. After 24 hours both 
chelates were completely cleared off from the tissues and organs with no deposition in 
the bones and liver/spleen. [67Ga](NOTAC8) showed high kinetic stability in blood 
serum. 
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1. Introduction 
Radiogallium chelates are of great interest in the field of medical imaging. 67Ga 
(t1/2 = 3.25 days), a γ emitter, is useful for -scintigraphy, while 68Ga (t1/2 = 68 min), a β+ 
emitter, is adequate for positron emission tomography (PET). 67/68Ga(III), with a very 
well known coordination chemistry, allows easy radiopharmaceutical preparation, as the 
radiometal can be very rapidly inserted in adequate molecules, contrarily to the 
covalently bound PET radioisotopes 18F or 11C, leading to a minimum loss of activity 
[1]. 
Ga(III) is a hard Lewis acid that forms thermodynamically stable chelates with 
ligands that are hard Lewis bases, often with a coordination number of six. The main 
requirements for a Ga(III)-based radiopharmaceutical agent are the thermodynamic 
stability towards hydrolysis and the kinetic inertness during the period of clinical use in 
order to avoid ligand exchange with the blood serum proteins, such as transferrin (Tf). 
Ga(III) is quite similar to the high spin Fe(III) ion in what concerns their ionic radii (62 
pm and 65 pm, respectively, when hexacoordinated), charge and coordination 
chemistry. Transferrin has two binding sites for Fe(III), that have also high affinity for 
Ga(III) (log K(Ga-Tf) = 20.3 [2]), and is present in high concentrations in plasma, 2.5 x 
10-3 M. Thus, when 67Ga(III) is injected in the form of gallium citrate (or another low 
stability complex) more than 90% of this metal is complexed by transferrin. 
 Several chelators for Ga(III) have been proposed, the majority of them being 
hexadentate [1, 3-11]. Among the chelators, triaza macrocycles display high 
conformational and size selectivity towards Ga(III) ions. The high thermodynamic 
stability of the Ga(III) chelates of nine-membered triaza ligands is due to the adequate 
fit of the relatively small cation in the macrocyclic cavity. The high thermodynamic 
stabilities of Ga(III) chelates of NOTA-like ligands are illustrated respectively by log 
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KGa(NOTA) = 30.98 and log KGa(NODASA) = 30.9(0.2) (NOTA = 1,4,7-triazacyclonoane-
N,N’N’’-triacetic acid; NODASA = 1,4,7-triazacyclonoane-N-succinic acid-N’N’’-
diacetic acid) [9, 12]. Their high resistance against exchange of Ga(III) in blood serum 
and acid-catalyzed dissociation has been demonstrated [9]. 
Some of the ligands currently used for the preparation of radiopharmaceuticals 
of Ga(III) are bifunctional, meaning that they present a functionality that allows 
covalent coupling to a targeting vector (e.g. peptides), besides binding the metal ion. 
The coupling to the targeting moiety requires that the pro-chelator, often bearing 
carboxylic acid groups, has the possibility of orthogonal protection [13].  
Micelles are colloidal aggregates that have been extensively used as drug 
carriers to improve pharmacokinetic properties or the bioavailability of the drug, to 
increase the target-to-background ratio of the drug or to deliver hydrophobic drugs [14-
17]. These self-assembly constructs accumulate in macrophage-rich tissues, such as 
liver and spleen, undergoing endocytosis/phagocytosis [14, 18]. Micelles loaded with 
suitable reporter groups can have application in medical imaging. Gd(III)-containing 
micelles are of interest as MRI contrast agents due to the possibility of delivery of high 
payloads of paramagnetic ion to the biological receptors and to the expected  increase in 
their relaxivity as a consequence of the slowing down of the rotational dynamics of the 
chelates upon aggregation [19, 20]. By their turn, radio-labeled (125I, 111In, 153Sm) 
micelles have been employed in -scintigraphic studies for the visualization of 
macrophage-rich tissues such as lymph nodes, liver and spleen [21-24]. 
In this work we envisaged the synthesis and the study of micelles-forming triaza 
chelates of Ga(III) potentially interesting for diagnosis in nuclear medicine. The 
synthetic route of this series of NOTA-based chelators, with one of the acetate pendant 
arms bearing a -alkyl substituent with a variable number of carbon atoms (from four to 
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fourteen - NOTAC6, NOTAC8, NOTAC10, NOTAC16, see Scheme 1) makes use of an 
orthogonal protection strategy, allowing their coupling to targeting biomolecules. 
A multinuclear NMR study (1H, 13C, 27Al and 71Ga) gave an insight on the 
structure and dynamic behavior of the metal chelates in solution. Al(III) chelates were 
used as models of the analogous Ga(III) chelates, due to the more suitable magnetic 
resonance properties of aluminum (100% abundance and fairly good receptivity) [4].  
The variation of the half-width of the 27Al NMR signal with concentration allowed the 
assessment of the critical micellar concentration (cmc) of the amphiphilic Al(III) 
chelates, consistent with the quadrupolar nature of the Al(III) ion. The cmc results were 
confirmed using a fluorescent method based on the use of ANS (8-anilino-1-napthalene 
sulfonic acid) [25].  
A very important indicator for in vivo applications is the measurement of the rate 
of exchange of Ga(III) in blood serum under physiological conditions [26]. For this 
purpose, the stability of the 67Ga(III) labeled chelates in blood serum was investigated. 
Biodistribution and -scintigraphic studies of the 67Ga(III) labeled chelates were 
performed in Wistar rats. 
 
2. Experimental 
2.1. Materials and methods 
 Analytical grade reagents were purchased from Sigma-Aldrich, Fluka, Acros 
Organics, Macrocyclics and Chematech. [67Ga](citrate) was purchased from CIS-BIO 
(Gif-sur- Yvette, France). The reactions were monitored by thin layer chromatography 
(TLC) on aluminum plates coated with silica gel 60 F254 (Macherey-Nagel). 
 Chromatography separations were performed on silica gel Whatman 230-240 
Mesh. The NMR spectra were recorded on a Varian Unity Plus 300 spectrometer or on 
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a Bruker Avance III 400 spectrometer. The 1H NMR spectra were assigned using the 
two-dimensional COSY technique. The 1H chemical shifts are reported in ppm, relative 
to tetramethylsilane (TMS) or sodium 2,2-dimethylsilapentane-5-sulfonate (DSS) and 
the following abbreviations are used: s = singlet; sb = broad singlet; d = doublet; dd = 
double doublet; t = triplet; tb = broad triplet; m = multiplet; mb = broad multiplet. 27Al 
NMR spectra were recorded at 104.261 MHz (on the Bruker Avance III 400 
spectrometer) using the signal of [Al(H2O)6]3+ at 0 ppm as reference. 71Ga NMR spectra 
were recorded at 122.026 MHz (on the same spectrometer) using the signal of 
[Ga(H2O)6]3+ at 0 ppm as reference. pH measurements were performed on a pH meter 
Crison micro TT 2050 with an electrode Mettler Toledo InLab 422. Mass spectra (ESI+) 
were performed on a VG Autospec M spectrometer or on a Finnigan LXQ MS Detector. 
2.2. Synthetic procedures 
2.2.1. Diphenyldiazomethane (1) 
 In a 1 L flask, benzophenonehydrazone (10.0 g, 51.0 mmol), yellow mercuric 
oxide (26.9 g, 124 mmol), anhydrous sodium sulfate (11.5 g, 81.0 mmol) and a 
saturated ethanol solution of KOH (3.80 mL) were suspended in ethyl ether (154 mL) 
and stirred for 75 min, according to the method published by Miller [27]. The solution 
was filtered and the solvent was evaporated under vacuum at room temperature. The 
dark red oil obtained was dissolved in petroleum ether 40-60ºC and filtered once again. 
The solvent was evaporated at room temperature and the residue was frozen. When 
heated to room temperature, the diphenyldiazomethane (DDM, 1) afforded dark red 
crystals (9.86 g, 50.8 mmol) in a yield of 99.6%. 
2.2.2. 2-bromohexanoate tert-butyl ester (2a) 
 A solution of tert-butyltrichloroacetimidate (TBTA) (5.00 g, 22.9 mmol) in 11.0 
mL of cyclohexane was added dropwise during 10 min to a solution of 2-
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bromohexanoic acid (0.815 mL, 5.72 mmol) in 10.0 mL of dichloromethane (DCM). 
During the addition, a white precipitate was formed, which was dissolved with the 
addition of 1.25 mL of N,N-dimethylacetamide. A catalyst, boron trifluoride ethyl 
etherate (BF3.OEt2) (0.700 mL), was added to the reaction and a new white precipitate 
was formed. The reaction was stirred during three days, according to the method 
published by Nicolle et al. [20]. The precipitate was removed by filtration and the 
solution was concentrated. The oil obtained was purified by chromatography 
(cyclohexane/ethyl acetate 7:3) originating a volatile brown oil 2a (1.16 g 4.62 mmol) 
in a yield of 80.5%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.91 (3H, t, J = 7.5 Hz, 
(CH2)2CH3), 1.29-1.40 (4H, m, (CH2)2CH3), 1.48 (9H, s, C(CH3)3), 1.86-2.10 (2H, m, 
CH2 ABX), 4.10 (1H, t, J = 7.5 Hz, CH ABX). 
2.2.3. 2-bromohexanoate benzhydryl ester (2b) 
 A solution of 2-bromohexanoic acid (3.70 mL, 26.0 mmol) in 160 mL of acetone 
was added to a solution of compound 1 (4.50 g, 23.2 mmol) in 160 mL of acetone. The 
reaction was stirred during 13 h in an ice bath and 10 h at room temperature. The 
solution was then concentrated and the yellow oil obtained was purified by 
chromatography (cyclohexane/ethyl acetate 4:1) affording the expected ester 2b with a 
yield of 93.1% (7.82 g, 21.6 mmol). 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.88 
(3H, t, J = 6.6 Hz, (CH2)2CH3), 1.22-1.48 (4H, m, (CH2)2CH3), 1.97-2.18 (2H, m, CH2 
ABX), 4.33 (1H, t, J = 7.2 Hz, CH ABX), 6.92 (1H, s, CH(Ph)2), 7.32-7.40 (10H, m, 
CH(Ph)2).  
2.2.4. 2-bromooctanoate benzhydryl ester (2c) 
 The title compound was prepared according to the method described for the 
preparation of 2b, starting from 2-bromooctanoic acid and using cyclohexane/ethyl 
acetate (9.5:0.5) as eluent in the chromatography. The compound 2c (5.10 g, 13.1 
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mmol) was obtained with a yield of 99.8%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 
0.89 (3H, t, J = 6.6 Hz, (CH2)4CH3), 1.24-1.30 (8H, m, (CH2)4CH3), 1.96-2.18 (2H, m, 
CH2 ABX), 4.34 (1H, t, J = 7.2 Hz, CH ABX), 6.92 (1H, s, CH(Ph)2), 7.34-7.39 (10H, 
m, CH(Ph)2). 13C NMR (75.43 MHz, CDCl3, TMS, (ppm)): 13.97 (1C, (CH2)4CH3), 
22.40-31.41 (4C, (CH2)4CH3), 34.88 (1C, CH2 ABX), 46.12 (1C, CH ABX), 78.18 (1C, 
CH(Ph)2), 127.02-139.45 (12C, CH(Ph)2), 168.69 (1C, CHCO). 
2.2.5. 2-bromodecanoate benzhydryl ester (2d) 
 The title compound was prepared according to the method described for the 
preparation of 2b, starting from 2-bromodecanoic acid and using cyclohexane/ethyl 
acetate (4:1) as eluent in the chromatography. The compound 2d (6.78 g, 16.2 mmol) 
was obtained with a yield of 98.8%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.95 
(3H, t, J = 6.3 Hz, (CH2)6CH3), 1.20-1.42 (12H, m, (CH2)6CH3), 2.00-2.22 (2H, m, CH2 
ABX), 4.38 (1H, t, J = 7.8 Hz, CH ABX), 6.97 (1H, s, CH(Ph)2), 7.33-7.45 (10H, m, 
CH(Ph)2).  
2.2.6. 2-bromohexadecanoate tert-butyl ester (2e) 
 The title compound was prepared according to the method described for the 
preparation of 2a, starting from 2-bromohexadecanoic acid. The purification was 
performed by recrystallization with methanol affording the ester 2e (3.11 g, 7.94 mmol) 
with a yield of 73.5%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.89 (3H, t, J = 5.1 
Hz, (CH2)12CH3), 1.26 (24H, s, (CH2)12CH3), 1.49 (9H, s, C(CH3)3), 1.87-2.10 (2H, m, 
CH2 ABX), 4.11 (1H, t, J = 9.9 Hz, CH ABX). 
2.2.7. 2-bromohexadecanoate benzhydryl ester (2f) 
 The title compound was prepared according to the method described for the 
preparation of 2b, starting from 2-bromohexadecanoic acid and using cyclohexane/ethyl 
acetate (4:1) as eluent in the chromatography. The compound 2f (6.04 g, 12.0 mmol) 
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was obtained with a yield of 93.8%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.93 
(3H, t, J = 6.3 Hz, (CH2)12CH3), 1.20-1.42 (24H, m, (CH2)12CH3), 1.98-2.20 (2H, m, 
CH2 ABX), 4.35 (1H, t, J = 7.2 Hz, CH ABX), 6.94 (1H, s, CH(Ph)2), 7.32-7.42 (10H, 
m, CH(Ph)2). 13C NMR (75.43 MHz, CDCl3, TMS, (ppm)): 14.11 (1C, (CH2)12CH3), 
22.67-31.90 (12C, (CH2)12CH3), 34.89 (1C, CH2 ABX), 46.12 (1C, CH ABX), 78.19 
(1C, CH(Ph)2), 127.03-139.46 (12C, CH(Ph)2), 168.68 (1C, CHCO). 
2.2.8. 1,4,7-triazacyclononane-N-hexanoate tert-butyl ester (3a) 
 A solution of 2a (0.747 g, 2.97 mmol) in 17.0 mL of DCM was added dropwise 
to a solution of 1,4,7-triazacyclononane (0.500 g, 3.87 mmol) in 26.0 mL of DCM. The 
reaction was stirred during 24 h. The white precipitate was filtered off and the solution 
was concentrated. The yellow residue obtained was purified by chromatography 
(DCM/EtOH 10:0 -> 7:3 and DCM/EtOH/NH3 7:3:0.5) giving rise to compound 3a 
(0.191 g, 0.638 mmol) with a yield of 21.5%. 1H NMR (300 MHz, CDCl3, TMS, 
(ppm)): 0.95 (3H, t, J = 6.6 Hz, (CH2)2CH3), 1.30-1.45 (4H, m, (CH2)2CH3), 1.47 (9H, 
s, C(CH3)3), 1.70-1.85 (2H, m, CH2 ABX), 2.60-3.65 (12H, m, en), 4.62 and 4.94 (1H, 
dd, J = 9.6 Hz and J = 10.2 Hz, CH ABX). m/z (ESI+) calculated for C16H34N3O2 
(M+H)+ 300.27. Found 300.25. 
2.2.9. 1,4,7-triazacyclononane-N-hexanoate benzhydryl ester (3b) 
 The title compound was prepared according to the method described for the 
preparation of 3a, starting from 2b. The yellow residue obtained was purified by 
chromatography (DCM/EtOH 9:1). The compound 3b (0.107 g, 0.261 mmol) was 
obtained with a yield of 32.2%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.83 (3H, 
t, J = 6.3 Hz, (CH2)2CH3), 1.20-1.37 (4H, m, (CH2)2CH3), 1.46-1.86 (2H, m, CH2 
ABX), 2.69-3.42 (12H, m, en), 4.43 and 4.76 (1H, dd, J = 9.9 and 9.6 Hz, CH ABX), 
6.86 (1H, s, CH(Ph)2), 7.20-7.30 (10H, m, CH(Ph)2). 
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2.2.10. 1,4,7-triazacyclononane-N-octanoate benzhydryl ester (3c) 
 The title compound was prepared according to the method described for the 
preparation of 3a, starting from 2c and was obtained with 35.2% yield (0.126 g, 0.288 
mmol). 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.86 (3H, t, J = 5.7 Hz, 
(CH2)4CH3), 1.21-1.40 (8H, m, (CH2)4CH3), 1.50-1.90 (2H, m, CH2 ABX), 2.72-3.26 
(12H, m, en), 4.47 and 4.77 (1H, dd, J = 9.6 and 9.9 Hz, CH ABX), 6.90 (1H, s, 
CH(Ph)2), 7.27-7.36 (10H, m, CH(Ph)2).  
2.2.11. 1,4,7-triazacyclononane-N-hexadecanoate tert-butyl ester (3e) 
 The title compound was prepared according to the method described for the 
preparation of 3a, starting from 2d. Compound 3e (0.132 mg, 0.300 mmol) was 
obtained with a yield of 17.2%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.87 (3H, 
t, J = 6.9 Hz, (CH2)12CH3), 1.25 (24H, s, (CH2)12CH3), 1.45 (9H, s, C(CH3)3), 1.68-1.81 
(2H, m, CH2 ABX), 2.76-3.56 (12H, m, en), 4.59 and 4.92 (1H, dd, J = 9.9 Hz, CH 
ABX). 
2.2.12. 1,4,7-triazacyclononane-N-hexanoate tert-butyl ester-N’-N’’-diacetate tert-
butyl ester (4a) 
 Potassium carbonate (0.279 g, 2.02 mmol) and 2-bromoacetate tert-butyl ester 
(0.142 mL, 0.964 mmol) were added to a solution of 3a (0.144 g, 0.481 mmol) in 21.0 
mL of acetonitrile (MeCN). After 24 h, the remaining potassium carbonate was filtered 
off and the solution was concentrated. The yellow oil obtained was purified by 
chromatography (DCM/EtOH 7:3). The compound 4a (0.147 g, 0.278 mmol) was 
obtained with a yield of 57.8%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.89 (3H, 
t, J = 7 Hz, (CH2)2CH3), 1.24-1.39 (4H, m, (CH2)2CH3), 1.45 (27H, s, C(CH3)3), 1.50-
1.70 (2H, m, CH2 ABX), 2.58-3.40 (17H, m, en, CH2CO, CH ABX). m/z (ESI+) 
calculated for C28H54N3O6 (M+H)+ 528.40. Found 528.42.  
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2.2.13. 1,4,7-triazacyclononane-N-hexanoate benzhydryl ester-N’-N’’-diacetate 
tert-butyl ester (4b) 
 The title compound was prepared according to the method described for the 
preparation of 4a, starting from 3b. The compound 4b (0.137 g, 0.215 mmol) was 
obtained with a yield of 82.4%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.84 (3H, 
t, J = 6.9 Hz, (CH2)2CH3), 1.20-1.40 (4H, m, (CH2)2CH3), 1.44 (18H, s, C(CH3)3), 1.45-
1.84 (2H, m, CH2 ABX), 2.60-3.60 (16H, m, en and CH2CO), 4.80 (1H, CH ABX), 6.88 
(1H, s, CH(Ph)2), 7.27-7.33 (10H, m, CH(Ph)2). 13C NMR (100.613 MHz, CDCl3, TMS, 
(ppm)): 13.81 (1C, (CH2)2CH3), 22.49 (1C, CH2CH2CH3), 27.87-28.06 (6C, C(CH3)3), 
28.75 (1C, CH2CH2CH3), 31.15 (1C, CH2 ABX), 50.62-68.12 (8C, en and CH2CO), 
59.21 (1C, CH ABX), 77.00 (1C, CH(Ph)2), 81.62-85.28 ( 2C, C(CH3)3), 126.52-139.88 
(12C, CH(Ph)2), 164.03 (1C, CHCO), 170.93-172.06 (2C, CH2CO). m/z (ESI+) 
calculated for C37H56N3O6 (M+H)+ 638.41691. Found 638.41671. 
2.2.14. 1,4,7-triazacyclononane-N-octanoate benzhydryl ester-N’-N’’-diacetate tert-
butyl ester (4c) 
 The title compound was prepared according to the method described for the 
preparation of 4a, starting from 3c. The compound 4c (0.093 g, 0.140 mmol) was 
obtained with a yield of 48.6%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.86 (3H, 
t, J = 6.3 Hz, (CH2)4CH3), 1.22-1.29 (8H, m, (CH2)4CH3), 1.45 (18H, s, C(CH3)3), 1.55-
1.80 (2H, m, CH2 ABX), 2.65-3.60 (16H, m, en and CH2CO), 3,99 and 4.30 (1H, dd, J 
= 17.4 and 17.1 Hz, CH ABX), 6.89 (1H, s, CH(Ph)2), 7.27-7.34 (10H, m, CH(Ph)2). 
13C NMR (100.613 MHz, CDCl3, TMS, (ppm)): 13.99 (1C, CH2CH2CH2CH2CH3), 
22.48 (1C, CH2CH2CH2CH2CH3), 26.59 and 29.11 (2C, CH2CH2CH2CH2CH3), 27.97 
(6C, C(CH3)3), 30.46 (1C, CH2 ABX), 31.63 (1C, CH2CH2CH2CH2CH3), 53.79-66.68 
(8C, en and CH2CO), 62.91 (1C, CH ABX), 76.94 (1C, CH(Ph)2), 81.20 ( 2C, C(CH3)3), 
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127.09-140.06 (12C, CH(Ph)2), 170.76-172.66 (3C, CH2CO and CHCO). m/z (ESI+) 
calculated for C39H60N3O6 (M+H)+ 666.448. Found 666.500. 
2.2.15. 1,4,7-triazacyclononane-N-decanoate benzhydryl ester-N’-N’’-diacetate tert-
butyl ester (4d) 
 Compound 2d (0.467 g, 1.12 mmol) was added to a solution of NO2AtBu 
(1,4,7-triazacyclononane-N,N’-diacetic acid tert-butyl ester) (0.401 g, 1.12 mmol) and 
K2CO3 (0.310 g, 2.25 mmol) in 30.0 mL of MeCN. The suspension was stirred during 4 
h and was filtered to remove the solid. The yellow oil obtained after concentration under 
vacuum was purified by column chromatography (DCM/EtOH 7:3). Compound 4d 
(0.753 g, 1.08 mmol) was obtained with a yield of 96.4%. 1H NMR (300 MHz, CDCl3, 
TMS, (ppm)): 0.88 (3H, t, J = 6.0 Hz, (CH2)6CH3), 1.15-1.35 (12H, m, (CH2)6CH3), 
1.45 (18H, s, C(CH3)3), 1.52-1.83 (2H, m, CH2 ABX), 2.60-4.00 (16H, m, en and 
CH2CO), 4.32 (1H, t, CH ABX), 6.90 (1H, s, CH(Ph)2), 7.27-7.36 (10H, m, CH(Ph)2). 
2.2.16. 1,4,7-triazacyclononane-N-hexadecanoate tert-butyl ester-N’-N’’-diacetate 
tert-butyl ester (4e) 
 The title compound was prepared according to the method described for the 
preparation of 4a, starting from 3e. Compound 4e (0.025 g, 0.037 mmol) was obtained 
with a yield of 12.3%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.87 (3H, t, J = 6.9 
Hz, (CH2)12CH3), 1.24 (24H, s, (CH2)12CH3), 1.45 (27H, s, C(CH3)3), 1.63-1.82 (2H, m, 
CH2 ABX), 2.64-4.90 (17H, m, en, CH ABX and CH2CO). 
2.2.17. 1,4,7-triazacyclononane-N-hexadecanoate benzhydryl ester-N’-N’’-
diacetate tert-butyl ester (4f) 
 The title compound was prepared according to the method described for the 
preparation of 4d, starting from 2f. Compound 4f (0.113 g, 0.145 mmol) was obtained 
with a yield of 74.0%. 1H NMR (300 MHz, CDCl3, TMS, (ppm)): 0.88 (3H, t, J = 6.3 
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Hz, (CH2)12CH3), 1.26 (24H, s, (CH2)12CH3), 1.45 (18H, s, C(CH3)3), 1.50-1.83 (2H, m, 
CH2 ABX), 2.60-4.40 (17H, m, en, CH ABX and CH2CO), 6.89 (1H, s, CH(Ph)2), 7.27-
7.36 (10H, m, CH(Ph)2). 
2.2.18. 1,4,7-triazacyclononane-N-hexanoic-N’-N’’-diacetic acid (NOTAC6) 
 5.00 mL of trifluoracetic acid (TFA) was added to a solution of 4a (0.092 g, 
0.174 mmol) in 5.00 mL of DCM and the reaction was stirred during 17 h. After that, 
the solvent and the remaining TFA were evaporated and the brown oil was washed three 
times with n-hexane to assure that all the TFA was removed. NOTAC6 (0.090 mg, 
0.128 mmol) was obtained with a yield of 73.6%. (The same method could be applied to 
the pro-chelators orthogonally protected). 1H NMR (300 MHz, D2O, DSS, pH = 1.31, 
(ppm)): 0.87 (3H, t, J = 7.0 Hz, (CH2)2CH3), 1.28-1.44 (4H, m, (CH2)2CH3), 1.75-1.98 
(2H, m, CH2 ABX), 3.28 (12H, s, en), 3.78 and 3.81 (1H, dd, J = 6.3 and 6.3 Hz, CH 
ABX), 3.92 (4H, s, CH2CO). 13C NMR (75.43 MHz, D2O, DSS, pH = 1.31, (ppm)): 
13.19 (1C, (CH2)2CH3), 22.08 (1C, CH2CH2CH3), 28.08 (1C, CH2 ABX), 28.26 (1C, 
CH2CH2CH3), 47.13- 50.28 (6C, en), 55.99 (2C, CH2CO), 66.23 (1C, CH ABX), 172.99 
(2C, CH2CO), 175.38 (1C, CHCO). m/z (ESI+) calculated for C16H30N3O6 (M+H)+ 
360.21346. Found 360.21241.  
2.2.19. 1,4,7-triazacyclononane-N-octanoic-N’-N’’-diacetic acid (NOTAC8) 
 The title compound was prepared according to the method described for the 
preparation of NOTAC6, starting from 4c. NOTAC8 (0.034 g, 0.088 mmol) was 
obtained with a yield of 79.3%. 1H NMR (300 MHz, D2O, DSS, (ppm)): 0.82 (3H, t, J 
= 6.6 Hz, (CH2)4CH3), 1.24-1.44 (8H, m, (CH2)4CH3), 1.70-2.00 (2H, m, CH2 ABX), 
3.28 (12H, s, en), 3.79 (1H, t, J = 7.8 Hz, CH ABX), 3.90 (4H, s, CH2CO). 13C NMR 
(75.43 MHz, D2O, DSS, (ppm)): 13.54 (1C, (CH2)4CH3), 22.11 (1C, 
CH2CH2CH2CH2CH3), 26.04 and 28.46 (2C, CH2CH2CH2CH2CH3), 28.34 (1C, CH2 
14 
ABX), 30.96 (1C, CH2CH2CH2CH2CH3), 47.35-50.40 (6C, en), 56.30 (2C, CH2CO), 
66.62 (1C, CH ABX), 173.04 (2C, CH2CO), 175.32 (1C, CHCO). m/z (ESI+) calculated 
for C18H33N3O6 (M+H)+ 388.24. Found 388.50. 
2.2.20. 1,4,7-triazacyclononane-N-decanoic-N’-N’’-diacetic acid (NOTAC10) 
 The title compound was prepared according to the method described for the 
preparation of NOTAC6, starting from 4d. NOTAC10 (0.569 g, 0.751 mmol) was 
obtained with a yield of 88.4%. 1H NMR (300 MHz, D2O, DSS, (ppm)): 0.86 (3H, tb, 
(CH2)6CH3), 1.15-1.50 (8H, mb, (CH2)6CH3), 1.60-1.96 (2H, mb, CH2 ABX), 2.95-3.25 
(12H, sb, en), 3.57 (1H, sb, CH ABX), 3.88 (4H, sb, CH2CO). 13C NMR (75.43 MHz, 
D2O, DSS, (ppm)): 13.87 (1C, (CH2)6CH3), 22.62-31.98 (6C, (CH2)6CH3), 28.60 (1C, 
CH2 ABX), 46.64-50.93 (6C, en), 55.62 (2C, CH2CO), 64.92 (1C, CH ABX), 171.95-
172.28 (2C, CH2CO), 174.93 (1C, CHCO). m/z (ESI+) calculated for C20H38N3O6 
(M+H)+ 416.28. Found 416.50. 
2.2.21. 1,4,7-triazacyclononane-N-hexadecanoic-N’-N’’-diacetic acid (NOTAC16) 
 The title compound was prepared according to the method described for the 
preparation of NOTAC6, starting from 4e or 4f. NOTAC16 (0.021 g, 0.029 mmol) was 
obtained with a yield of 78.4%. 1H NMR (300 MHz, CD3OD, TMS, (ppm)): 0.92 (3H, 
t, J = 6.6 Hz, (CH2)12CH3), 1.31 (24H, s, (CH2)12CH3), 1.70-2.20 (2H, m, CH2 ABX), 
2.80-3.37 (12H, m, en), 3.62 (1H, t, J = 7.2 Hz, CH ABX), 3.70-4.00 (4H, sb, CH2CO). 
m/z (ESI+) calculated for C26H50N3O6 (M+H)+ 500.36996. Found 500.36711. 
2.2.22. [Al(NOTAC6)] 
 Aluminum nitrate and NOTAC6 dissolved in water were added in equimolar 
amounts (Scheme 2). The pH was adjusted from 1.7 to 3.0 with 1 M KOH solution. The 
solution was stirred for 1 h at 75ºC. After it reached room temperature, the pH was fixed 
to 4.0. The water was evaporated and a 20.0 mM solution of the chelate in D2O was 
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prepared to perform the multinuclear NMR characterization. 1H NMR (300 MHz, D2O, 
DSS, (ppm)): 0.92 (3H, t, J = 7.2 Hz, (CH2)2CH3), 1.32-1.50 (2H, m, CH2CH2CH3, 
1.53-1.63 (2H, m, CH2CH2CH3), 1.75-1.90 and 2.04-2.16 (2H, m, CH2 ABX), 2.84-3.71 
(13H, m, en and CH ABX), 3.82 (4H, d, J = 10.8 Hz, CH2CO). 13C NMR (100.613 
MHz, D2O, SiMe4, pH = 5.20, ): 13.06 (1C, (CH2)2CH3), 22.04 (1C, CH2CH2CH3), 
25.31 (1C, CH2 ABX), 29.09 (1C, CH2CH2CH3), 44.39- 54.06 (6C, en), 62.92 (2C, 
CH2CO), 68.61 (1C, CH ABX), 175.47 (2C, CH2CO), 176.94 (1C, CHCO). 27Al NMR 
(104.261 MHz, H2O/D2O (75/25%), [Al(H2O)6]3+, (ppm)): 47.58 ([Al(NOTAC6)]) 
(ω1/2 = 51.31 Hz). 
2.2.23. [Ga(NOTAC6)] 
 Gallium nitrate and NOTAC6 dissolved in water were added in equimolar 
amounts. The pH was adjusted from 1.8 to 5.7 with 1 M KOH solution. The solution 
was stirred for 1 h at 75ºC. The water was evaporated and a 20.0 mM solution of the 
chelate in D2O was prepared to perform the multinuclear NMR characterization. 1H 
NMR (300 MHz, D2O, DSS, (ppm)): 0.93 (3H, t, J = 7.2 Hz, (CH2)2CH3), 1.26-1.51 
(2H, m, CH2CH2CH3), 1.53-1.64 (2H, m, CH2CH2CH3), 1.70-1.90 and 2.06-2.18 (2H, 
m, CH2 ABX), 2.86-3.68 (13H, m, en and CH ABX), 3.83 (4H, d, J = 10.5 Hz, 
CH2CO). 13C NMR (75.43 MHz, D2O, DSS, pH = 5.20, ): 13.21 (1C, (CH2)2CH3), 
22.20 (1C, CH2CH2CH3), 25.91 (1C, CH2 ABX), 29.31 (1C, CH2CH2CH3), 44.05- 
53.84 (6C, en), 61.98 (2C, CH2CO), 68.67 (1C, CH ABX), 175.16 (2C, CH2CO), 
176.85 (1C, CHCO). 71Ga NMR (122.026 MHz, D2O, [Ga(H2O)6]3+, ): 165.48 
([Ga(NOTAC6)]) (ω1/2 = 528.45 Hz). m/z (ESI+) calculated for C16H26GaN3O6K 
(M+K)+ 464.07. Found 464.42. 
2.2.24. [Al(NOTAC8)] 
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 Aluminum nitrate and NOTAC8 dissolved in water were added in equimolar 
amounts. The pH was adjusted from 1.9 to 2.7 with 1 M KOH solution. The solution 
was stirred for 1 h at 75ºC. After it reached room temperature, the pH was fixed to 4.1. 
The water was evaporated and a 4.28 mM solution of the chelate in D2O was prepared 
to perform the multinuclear NMR characterization. 1H NMR (300 MHz, D2O, DSS, 
(ppm)): 0.88 (3H, t, J = 6.9 Hz, (CH2)4CH3), 1.22-1.67 (8H, m, (CH2)4CH3), 1.72-1.88 
and 2.02-2.18 (2H, m, CH2 ABX), 2.82-3.62 (12H, m, en), 3.67 (1H, t, J = 6.3 Hz, CH 
ABX), 3.82 (4H, s, CH2CO). 13C NMR (100.613 MHz, D2O, DSS, (ppm)): 13.27 (1C, 
(CH2)4CH3), 21.79 and 30.72 (2C, CH2CH2CH2CH2CH3), 25.50 (1C, CH2 ABX), 26.80 
and 28.24 (2C, CH2CH2CH2CH2CH3), 44.56-54.18 (6C, en), 63.10 (2C, CH2CO), 68.82 
(1C, CH ABX), 175.34 (2C, CH2CO), 176.63 (1C, CHCO). 27Al NMR (104.261 MHz, 
D2O, [Al(H2O)6]3+, (ppm)): 47.47 ([Al(NOTAC8)]) (ω1/2 = 54.87 Hz). 
2.2.25. [Ga(NOTAC8)] 
 Gallium nitrate and NOTAC8 dissolved in water were added in equimolar 
amounts. The pH was adjusted from 2.1 to 3.0 with 1 M KOH solution. The solution 
was stirred for 1 h at 75ºC. After it reached room temperature, the pH was fixed to 4.8. 
The water was evaporated and a 4.20 mM solution of the chelate in D2O was prepared 
to perform the multinuclear NMR characterization. 1H NMR (300 MHz, D2O, DSS, 
(ppm)): 0.88 (3H, t, J = 6.9 Hz, (CH2)4CH3), 1.31-1.53 (8H, m, (CH2)4CH3), 1.75-1.90 
and 2.05-2.20 (2H, m, CH2 ABX), 2.90-3.55 (12H, m, en), 3.65 (1H, t, J = 5.7 Hz, CH 
ABX), 3.83 (4H, m, CH2CO). 13C NMR (100.613 MHz, D2O, DSS, (ppm)): 13.27 
(1C, (CH2)4CH3), 21.79 (1C, CH2CH2CH2CH2CH3), 26.03 (1C, CH2 ABX), 26.85 and 
28.23 (2C, CH2CH2CH2CH2CH3), 30.71 (1C, CH2CH2CH2CH2CH3), 44.16-53.71 (6C, 
en), 61.95 (2C, CH2CO), 68.83 (1C, CH ABX), 174.79 (2C, CH2CO), 176.39 (1C, 
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CHCO). 71Ga NMR (122.026 MHz, D2O, [Ga(H2O)6]3+, (ppm)): 165.75 
([Ga(NOTAC8)]) (ω1/2 = 621.80 Hz). 
2.2.26. [Al(NOTAC10)] 
 Aluminum nitrate and NOTAC10 dissolved in water were added in equimolar 
amounts. The pH was adjusted to 3.0 with 1 M KOH solution, occurring precipitation. 
The solution was stirred for 1 h at 75ºC. The water was evaporated and a solution of the 
solid in CD3OD/D2O (3:1) was prepared to perform the NMR characterization. 27Al 
NMR (104.261 MHz, CD3OD/D2O (3:1), [Al(H2O)6]3+, (ppm)): 47.31 
([Al(NOTAC10)]) (ω1/2 = 145.59 Hz). 
2.2.27. [Al(NOTAC16)] 
 Method 1: Aluminum nitrate and NOTAC16 dissolved in water were added in 
equimolar amounts. The pH was adjusted from 2.0 to 3.0 with 1 M KOH solution. The 
solution was stirred for 1 h at 75ºC. After it reached room temperature, the pH was fixed 
to 4.0. The water was evaporated and a solution of the solid in D2O was prepared to 
perform the NMR characterization. 27Al NMR (104.261 MHz, D2O, [Al(H2O)6]3+, 
(ppm)): no signal was found. 
 Method 2: Aluminum nitrate dissolved in water and NOTAC16 dissolved in 
EtOH were added in equimolar amounts. The solution was stirred for 1 h at 75ºC. After 
it reached room temperature, the pH was fixed to 2.5 with 1 M KOH solution. The 
white precipitate formed with the addition of base was filtered off and the solution was 
evaporated. A solution of the solid in CD3OD was prepared to perform the NMR 
characterization. 27Al NMR (104.261 MHz, CD3OD, [Al(H2O)6]3+, (ppm)): 47.87 
(weak signal). 
2.2.28. [Ga(NOTAC16)] 
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 Gallium nitrate dissolved in MeOH and NOTAC16 dissolved in EtOH were 
added in equimolar amounts. The pH was adjusted from 0.8 to 2.8 with 1 M KOH 
solution. The solution was stirred for 1 h at 75ºC. The solvent was evaporated and a 
solution of the solid in CD3OD was prepared to perform the NMR characterization. 
71Ga NMR (122.026 MHz, CD3OD, [Ga(H2O)6]3+, (ppm)): no signal was found. 
2.3. Determination of the critical micellar concentration 
 The chelates were prepared by adding an appropriate amount of metal nitrate to 
a weighted quantity of ligand, dissolving in water at pH 4 and heating at 75oC during 
one hour. The water was evaporated and the solid was re-dissolved in phosphate buffer 
pH 7.4 or D2O. In order to know the exact number of ligand equivalents existing in a 
weighted amount of ligand, an excess of a standard Al(III) solution was added to a 
weighted quantity of chelator, leaving the complexation to occur during one hour at 
75oC. To this solution was added an excess of standard EDTA solution and this was 
back-titrated with a standard Ca(II) solution using eriochrome black T as indicator [28].  
2.3.1. 27Al NMR method 
 The determination of the critical micellar concentration (cmc) was performed by 
monitoring the variation of the half-width of the 27Al NMR signal with the variation of 
the chelate concentration [4]. Stock solutions of [Al(NOTAC6)] and [Al(NOTAC8)] in 
D2O, 13.0 mM and 4.28 mM respectively, were prepared at room temperature at pH 4.0. 
These concentrations were close to the limit of solubility of the chelates. The stock 
solutions were then gradually diluted in D2O and 27Al NMR spectra were recorded for 
each concentration of chelate. 
2.3.2. Fluorescence method 
 The estimation of the critical micellar concentration (cmc) was also performed 
by fluorescence using 8-anilinonaphthalene-1-sulfonate (ANS) as fluorescence probe 
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[29]. Stock solutions of 16.63 mM of [Ga(NOTAC6)] and 3.36 mM of [Ga(NOTAC8)] 
were prepared in 0.1 M and 0.2 M phosphate buffer pH 7.4, respectively. These 
concentrations were close to the limit of solubility of the chelates. Solutions with 
different chelate concentrations, prepared by dilution of the stock solutions, containing 
1x10-5 M ANS were used in this study. The fluorescence was measured at 480 nm upon 
excitation at 350 nm at room temperature. The fluorescence measurements were 
recorded on a Bio-Tek® SynergyTM HT spectrofluorimeter using the software KC4TM. 
2.4. Radiochemistry 
 [67Ga] chelates for in vivo and in vitro experiments were prepared by adding 1 
mCi of [67Ga](citrate) to a solution of 1 mg of the chelator in HEPES (0.150 mL, 0.1 M, 
pH 5) and heated at 80ºC for ca 1 h. The radiochemical purity of the [67Ga]L solutions 
were determined by thin layer chromatography (TLC), and the percentage of bound 
metal averaged 96%. 
2.4.1. Determination of logP and stability in blood serum 
 The octanol/water partition coefficient (logP) of [67Ga](NOTAC6) and 
[67Ga](NOTAC8) was determined using the shake-flask method. The partition 
coefficient was determined by adding 25 L of the chelate solution to a tube containing 
1 mL of saline solution and 1 mL of 1-octanol. The resulting mixture was shaken at 
room temperature for 1 h and then centrifuged at 3000 rpm during 3 min. After the 
centrifugation, 100 L of each phase was collected and the activity was measured. The 
partition coefficient was calculated as a ratio of the counts in the octanol fraction to the 
counts in the water fraction being this the result of the average of 5 determinations (S.D. 
< 0.01). 
 For the blood serum stability studies, 5 Ci of the standard solution of 
[67Ga](NOTAC8) were added to 5 mL of fresh human serum, previously equilibrated in 
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5% CO2 (95% air) environment at 37ºC. The mixture was stored in the same 
environment conditions, and aliquots of 100 mL (in triplicate) were taken at appropriate 
periods of time (0 min, 30 min, 1 h and 3 h). The aliquots were treated with 200 L of 
ethanol, cooled (4ºC), and centrifuged during 15 min at 4000 rpm, at 4ºC, in order to 
precipitate the serum proteins. A 100 L aliquot of supernatant was collected for 
activity counting in a  well-counter. The sediment was washed twice with 1 mL of 
EtOH and its activity was counted. The activity of the supernatant was compared to that 
of the sediment in order to determine the percentage of the chelate associated to the 
proteins. The activity of the supernatant at 3 h was evaluated by TLC in order to check 
whether the chelate remained intact.   
2.4.2. Biodistribution 
 Methods: A gamma camera-computer system (GE 400 GenieAcq, from General 
Electric, Milwaukee, WI, USA) was used for acquisition and pre-processing the in vivo 
gamma imaging. Data processing and display were performed on a personal computer 
using homemade software developed for the IDL 6.3 (Interactive Data Language, 
Research Systems, Boulder, CO, USA) computer tool.  
 Biodistribution studies: Groups of four animals (Wistar rat males weighting ca 
200 g) were anaesthetized with Ketamine (50.0 mg/ml)/chloropromazine (2.5%) (10:3) 
and injected in the tail vein with ca 100 Ci of the tracer and sacrificed 30 min and 24 h 
later. The major organs were removed, weighted and counted in a  well-counter.  
 In vivo gamma imaging: The animals were positioned in ventral decubitus over 
the detector. Image acquisition was initiated immediately before radiotracer injection in 
the tail vein. Sequences of 30 images (of 60 s each), were acquired to 6464 matrices. 
In addition, static data were acquired 24 h after the radiotracer injection (180X180 
matrices, time = 10 min). Images were subsequently processed using an IDL based 
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program. In order to analyze the transport of radiotracer over time, three regions of 
interest (ROI) were drawn on the image files, corresponding to the thorax, liver and left 
kidney. From these regions, time-activity curves were obtained and normalized to the 
maximum activity in all the organs. 
 
3. Results and discussion 
3.1. Synthesis  
 We followed two different synthetic approaches for the preparation of the 
chelators. In the first method both alkylating agents were protected in the form of tert-
butyl ester, which allowed obtaining pro-chelators 4a and 4e (C and D in Scheme 1). 
Their reaction with TFA afforded the chelators NOTAC6 and NOTAC16. The other 
method involved the mono-alkylation of the triazacyclononane moiety using the 
alkylating agents protected in the form of benzhydryl ester (C in Scheme 1) originating 
intermediates 3b and 3c. Their reaction with 2-bromoacetate tert-butyl ester afforded 
the pro-chelators 4b and 4c, which are orthogonally protected. Treating 4b and 4c with 
TFA afforded the totally unprotected chelators NOTAC6 and NOTAC8. As the 
preparation of the mono-alkylated intermediates involves low yield synthesis we 
alternatively started with NO2AtB (a triazacyclononane moiety with two acetate 
pendant arms protected with tert-butyl groups) shortening the synthetic pathway and 
affording the pro-chelators 4d and 4f in good yield (E in Scheme 1). Their treatment 
with TFA afforded the chelators NOTAC10 and NOTAC16. 
3.2. Characterization of the Al(III) and Ga(III) chelates by multinuclear NMR 
 Octahedral metal chelates of NOTA can have two possible arrangements for the 
coordination of the acetate groups, while the ethylenic bridges of the macrocyclic ring 
can also adopt two different orientations [30]. According to this, the chelates of NOTA 
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become chiral. Depending on the torsion angle of the acetate groups, the isomers can be 
clockwise () or anticlockwise (). The orientation of the ethylenic bridges originates 
the isomers and. Therefore, two enantiomeric pairs are possible: type I [() and 
()] and type II [() and ()]. The solid state structures of Ga(NOTA) and 
Al(NOTA) have been previously determined [6, 31], showing coordination of the metal 
ion to the three ring nitrogen atoms, as well as to three carboxylate oxygen atoms, 
yielding a pseudo-octahedral arrangement corresponding to the type I enantiomeric pair. 
The introduction of the aliphatic chain in the structures of the ligands produces a chiral 
carbon (R and S configurations), leading to another factor for enantiomerism. 
Accordingly, each of the chelates of NOTAC6, NOTAC8, NOTAC10 and NOTAC16 
may originate four diastereoisomeric pairs of enantiomers in solution. 
 The 1H NMR results obtained for the Al(III) and Ga(III) chelates of NOTAC6 
and NOTAC8 in aqueous solution (illustrated in Figures 1, S3 – S4 for NOTAC8) are in 
agreement with the structures determined for the respective NOTA chelates by X-ray 
crystallography. These systems show symmetrical and well resolved resonances 
corresponding to the ring protons which create AA’MM’ multiplet patterns arising from 
the ()() ring conformational interconvertions. The -CH2 protons on the alkyl 
side chain become unequivalent upon coordination. The very similar patterns in the 1H 
NMR spectra of the Al(III) and Ga(III) chelates of NOTAC6 and NOTAC8  observed at 
two different temperatures (25°C and 75°C, see Figures 1, S3 – S4) are consistent with a 
slow exchange regime and with the high rigidity of NOTA-based systems in solution, 
with two possible configurational arrangements for the coordinated acetate groups and 
the puckering of the ethylenediamine metal-chelate rings [30]. The 1H NMR spectra 
recorded at chelate concentrations above and below the cmc show no differences 
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(Figure S4), indicating that the dynamic behavior of the chelates is not influenced by the 
micellization. 
 Despite the fact that it was not possible to obtain mono crystals suitable for X-
ray diffraction, some useful structural information about the coordination site of the 
cations can be obtained from metal NMR data. The 27Al and 71Ga NMR chemical shifts 
of the chelates in aqueous solution (Table 1) are within the range usually found for 
octahedral or pseudo-octahedral species with a C3 symmetry axis, responsible for the 
high symmetry at the coordination metal centre [4]. X-ray crystallography studies of 
Al(III) and Ga(III) chelates of NOTA [3, 31-34] and NOTA-based ligands [35-37] 
showed that these chelates have pseudo-octahedral geometries. 
 The complexation process of the metal ions with NOTAC10 and NOTAC16 was 
limited by the poor water solubility of the ligands, as monitored by the 27Al NMR 
spectra. The [Al(NOTAC10)] complex was formed in aqueous solution, originating a 
27Al NMR signal at 47.31 ppm, much weaker than the main resonance from 
[Al(H2O)6]3+ (0 ppm). NOTAC16 had very poor solubility in water and it was not 
possible to obtain the Al(III) and Ga(III) chelates in aqueous solution. However, when 
the Al(III) chelate was prepared in ethanol, a weak 27Al NMR signal at 47.87 ppm could 
be detected. 
The 27Al NMR signals of the Al(III) chelates bearing short side chains 
(NOTAC6 and NOTAC8) show half-widths (ω1/2) similar to those found for the 
Al(III) chelate of NOTA, but they become significantly broader for the chelates with 
longer side chains [38]. Such an increased broadening with side chain length increase is 
more marked for the 71Ga resonance of the Ga(III) complexes [36] (Table 1). These 
observations result from the quadrupolar relaxation of the metal nuclei and the slowing 
down of the rotational dynamics of the heavier complexes in solution. 
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3.3. Determination of the critical micellar concentration 
 The amphiphilic behavior of the metal chelates of NOTAC6 and NOTAC8 was 
demonstrated by determining their critical micellar concentration. For this purpose, two 
distinct methods were used. In one method, the fluorescence of ANS (8-anilino-1-
naphtalene sulfonic acid), which is sensitive to the polarity of the environment, showing 
no fluorescence in water and high fluorescence in non-polar environments, was used as 
a probe for the Ga(III) chelates. Entrapping ANS in the inner part of the micelle, which 
is non-polar, increases the intensity of its fluorescence [29]. The cmc value was 
estimated by linear least-square fitting of the fluorescence emission at 480 nm versus 
the concentration of the chelates (Figure 2). The calculated cmc values were 5.20 mM 
for [Ga(NOTAC6)] and 0.36 mM for [Ga(NOTAC8)], showing that the two chelates 
have quite different aggregation behaviors, as an increase of alkyl chain length from 
four to six carbons decreases the cmc by an order of magnitude, reflecting a strong 
increase of the self-aggregation capacity of the chelates. The fact that the fluorescence 
intensity of the [Ga(NOTAC6)] system increases with the increase of concentration of 
chelate until the cmc value is reached suggests the formation of  pre-micellar 
aggregates, contrary to what happens for [Ga(NOTAC8)]. The existence of pre-micellar 
aggregation has been detected before [23], by using DLS to prove the existence of 
aggregates of [Gd(EPTPAC16)]2- (EPTPAC16 = (hydroxymethylhexadecanoyl ester) 
ethylenepropylenetriaminepentaacetic acid) with dimensions superior to 100 nm below 
the cmc. The formation of aggregates at concentrations below the cmc was also verified 
by fluorescence correlation spectroscopy in such reduced amount that the conventional 
techniques were not able to detect it [39]. 
 On the other hand, the cmc values of [Al(NOTAC6)] and [Al(NOTAC8)] were 
assessed using 27Al NMR spectroscopy. Due to the quadrupolar nature of the 27Al 
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nuclide, whose nuclear relaxation is dependent on the rotational correlation time of the 
chelate in solution [4], the linear least-square fitting of the plot of the half-width of the 
27Al NMR signal as a function of the chelate concentration (Figure 3) allowed obtaining 
the cmc values. The plot for [Al(NOTAC8)], with a single break, reflected a simple 
micellization process with a cmc value of 0.25 mM, consistent with the value found by 
fluorescence for the analogous Ga(III) chelate. The corresponding plot for 
[Al(NOTAC6)] showed two breaks, at 1.16 mM and 4.30 mM, reflecting a more 
complex micellization behavior. While the second value (4.30 mM) corresponds quite 
well to the cmc value detected for the Ga(III) complex by fluorescence, the first value 
(1.16 mM) suggests the formation of pre-micellar aggregates in solution, in agreement 
with what has been found by fluorescence for the corresponding Ga(III) complex. 
 The cmc values obtained for the studied chelates are within the range of those 
found for amphiphilic Ni(II) chelates of triaza-based ligands with comparable alkyl 
chain lengths [40].  
3.4. Determination of logP (and stability in blood serum) 
 The measured octanol/water partition coefficients (logP) of [67Ga](NOTAC6) 
and [67Ga](NOTAC8), respectively logP = -2.25 and logP = -1.19, revealed that the 
chelates present low lipophilicity which, as expected, increases when the chain length of 
the -alkyl substituent at one of the pendant acetate arms increases from C4 to C6.  
3.5. Stability in blood serum  
 Incubation studies of [67Ga](NOTAC8) in fresh human serum, followed by 
precipitation of its protein content, showed that the percentage of the activity in the 
protein pellet steadily increased with the incubation time (13.8% at 30 min, 30.8% at 60 
min), reaching a value of 36.7% at 3 h. This increasing activity associated to the blood 
proteins reflects the hydrophobic interactions involving the-alkyl substituent at one of 
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the acetate pendant arms and hydrophobic regions of the proteins. Nevertheless, it was 
found by TLC analysis that the radioactivity present in this fraction, after 3 h of 
incubation, represents the intact radiochelate, reflecting the high stability of 
[67Ga](NOTAC8) with regard to transchelation.  
3.6. Biodistribution and imaging studies 
 The biodistribution data for [67Ga](NOTAC8) and [67Ga](NOTAC6) are 
expressed as the percentage of injected dose per gram of tissue (%ID/g) in Figure 4. 
Both chelates are excreted by kidneys but the hepatobiliary pathway (stated as the sum 
of liver and intestines) has also a strong contribution. This is particularly evident from 
the scintigraphic studies. However, from our results, [67Ga](NOTAC8) seems to be 
more hepatospecific (1.28% of the activity is present in hepatobiliary transit at 30 min) 
than the corresponding C6 compound (hepatobiliary contribution at the same time 
equals 0.26%). These findings correlate with the higher lipophilicity of 
[67Ga](NOTAC8). This chelate also shows a much higher lung uptake than 
[67Ga](NOTAC6) chelate at 30 min, which is not persistent at longer times, as opposed 
to what has been found for the long chain tracer [153Sm](EPTPAC16)]2- [23]. 
Scintigraphic images of Wistar rats were obtained as a function of time after 
injection of the [67Ga](NOTAC6) tracer. Figure 5 compares the images obtained 2 min, 
4 min and 24 h after injection of the radiotracer, where various organs are enhanced. 
Time–activity curves for the [67Ga](NOTAC6) tracer (Figure 6) were obtained from 
scintigraphic dynamic acquisition experiments. The curves were smoothed and 
normalized in relation to the maximum radioactivity obtained. From these curves one 
can notice that the activity increased sharply in the thorax, liver and kidneys 
immediately after the injection, possibly corresponding essentially to blood activity. 
The highest value for liver and thorax was obtained after one minute, while it took 
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about two minutes to reach maximum activity at the kidneys. After reaching this 
maximum, the radioactivity in the liver and thorax decayed relatively slowly while for 
the kidneys it was almost constant during all the acquisition. At 30 min, the activity at 
the kidneys remained at 99% of the maximum attained while for liver and kidneys these 
values were 69% and 38%, respectively. We obtained the same information from the 
images presented in Figure 5 where only the kidneys and bladder are clearly visible. 
From these findings we can conclude that at least for [67Ga](NOTAC6), despite the 
contribution of the hepatobiliary mechanism for the radiotracer elimination, the main 
excretion mechanism is the kidney pathway. This is in accordance with the logP 
obtained for [67Ga](NOTAC6). 
 From the biodistribution data (for the two compounds) and from the imaging 
results for the NOTAC6 radiotracer, it is noticeable that most of the radioactivity was 
cleared off from tissues and organs within 24 h with virtually no deposition in the bones 
and liver/spleen, demonstrating the high in vivo stability of [67Ga](NOTAC6) and 
[67Ga](NOTAC8). 
 From the specifications of the supplier of [67Ga](citrate) (CIS-BIO, Gift-sur- 
Yvette, France), less than 4.5 ng of Ga(III) (1 mCi) of Ga(III) should be present in the 
final solution of [67Ga](NOTAC8) or [67Ga](NOTAC6). Thus, in both cases, the 
concentrations were well below the cmc determined for the complexes, and no micelles 
were supposed to be present in solution.  
 
 
 
4. Conclusions 
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 We developed a small library of four amphiphilic NOTA-based chelators 
presenting a -alkyl chain of variable size. The synthetic strategy that was used in this 
work may also be compatible with the preparation of bifunctional chelators which can 
be covalently coupled to targeting biomolecules bearing an amine function (eg. 
peptides). This is of paramount importance regarding receptor mediated medical 
imaging and radiotherapeutic applications. 
The metal chelates of NOTAC6 and NOTAC8 show distinct amphiphilic 
behavior. The shorter-size-chain chelate shows some level of pre-aggregation 
additionally to the formation of micelles. When the -alkyl chain has more than six 
carbon atoms, the chelators show low solubility in water, thus reducing the possibility 
of using their neutral chelates in biological applications.  
The increase in the size of the-alkyl chain, and the corresponding increase in 
the lipophilicity of the chelates (logP values), are responsible for a higher uptake of the 
Ga(III) chelates in the liver. From the imaging and biodistribution studies we can 
conclude that [67Ga](NOTAC8) and [67Ga](NOTAC6) present high in vivo stability and 
are excreted quite quickly, co-existing the kidney and hepatobiliary pathway. 
The fact that the radiolabeled chelates were injected at concentrations below the 
determined cmc, precluded the formation of micelles in vivo with consequent lower 
hepatic uptake than expected.  
 
5. Abbreviations 
%ID/g = percentage of injected dose per gram of tissue 
ANS = 8-anilino-1-naphtalene sulfonic acid 
cmc = critical micellar concentration 
DLS = dynamic light scattering 
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EDTA = ethylenediaminetetraacetic acid 
EPTPAC16 = (hydroxymethylhexadecanoyl ester) ethylenepropylenetriaminepentaacetic 
acid 
HEPES =  N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
IDL = interactive data language 
L = ligand 
MRI = Magnetic Resonance Imaging 
NO2AtB = 1,4,7-triazacyclononane-N,N’-diacetic acid tert-butyl ester 
NODASA = 1,4,7-triazacyclononane-N-succinic acid-N’,N’’-diacetic acid 
NOTA = 1,4,7-triazacyclononane-N,N’,N’’-triacetic acid 
NOTAC6 = 1,4,7-triazacyclononane-N-hexanoic acid-N’,N’’-diacetic acid 
NOTAC8 = 1,4,7-triazacyclononane-N-octanoic acid-N’,N’’-diacetic acid 
NOTAC10 = 1,4,7-triazacyclononane-N-decanoic acid-N’,N’’-diacetic acid 
NOTAC16 = 1,4,7-triazacyclononane-N-hexadecanoic acid-N’,N’’-diacetic acid 
PET = positron emission tomography  
ROI = regions of interest 
Tf  = transferrin 
TFA = trifluoracetic acid 
TLC = thin layer chromatography 
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and [Al(NOTAC8)] (25ºC, pH 4.00, at 4.28 mM and 0.15 mM) (Figure S4).  
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Table 1 – 27Al and 71Ga NMR chemical shifts and signal half-widths of Al(III) and 
Ga(III) chelates of NOTA derivatives in aqueous solution (25ºC) compared to those for 
NOTA.  
 27Al NMR 71Ga NMR 
Ligand  (ppm) ω1/2 (Hz)  (ppm) ω1/2 (Hz) 
NOTA  49 [38] 60 [38] 171 [36] 210 [36] 
NOTAC6 47.6a 51.3 165.5b 528.5 
NOTAC8 47.5c 55.0 165.8d 621.8 
NOTAC10 47.3e 145.6 - - 
NOTAC16 47.9f - - - 
a 20.0 mM, pH 4.0; b 20.0 mM, pH 5.7; c 4.28 mM, pH 4.1; d 4.20 mM, pH 4.8; e Concentration not 
defined, pH 3.0; f Methanol solution with concentration not defined, pH 2.5. 
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Scheme 1 – A – i) Solution of TBTA in cyclohexane added to the bromoacid dissolved 
in DCM; ii) DMA; iii) BF3.OEt2. B – Solution of DDM in acetone added to the 
bromoacid dissolved in acetone. C – Addition of ester solution in DCM to the 1,4,7-
triazacyclononane solution in DCM; D – K2CO3 and tert-butyl bromoacetate in MeCN; 
E – K2CO3 and NO2AtBu ester in MeCN; F – TFA/DCM (1:1).  
 
Scheme 2 – A – Al(NO3)3.9H2O in H2O; B – Ga(NO3)3.xH2O in H2O. 
 
Figure 1 – A – 1H NMR spectrum of [Al(NOTAC8)] (400 MHz, D2O, 75ºC, pH 4.10). 
B – 1H COSY spectrum of [Al(NOTAC8)].  
 
Figure 2 – Fluorescence intensity of the ANS fluorophore at 480 nm versus: A – 
[Ga(NOTAC6)] concentration; B – [Ga(NOTAC8)] concentration. The cmc values are 
established from graphical break points.  
 
Figure 3 – Half-width of the 27Al NMR signal of Al(III) chelates versus chelate 
concentration: A  – [Al(NOTAC6)]; B – [Al(NOTAC8)].  
 
Figure 4 – Biodistribution profile for Wistar rats (percentage of the injected dose/g of 
organ) of [67Ga](NOTAC6) (white bars) and [67Ga](NOTAC8) (gray bars) at 30 min (A) 
and 24 h (B) after injection.  
 
Figure 5 – Scintigraphic images at 2 min, 4 min and 24 h of a Wistar rat injected with 
[67Ga](NOTAC6).  
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Figure 6 – Time/activity curves of [67Ga](NOTAC6) obtained from dynamic images of 
the regions of interest of a Wistar rat. Kidneys (); Liver (); Thorax (▲). 
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